- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced or metastatic oesophageal squamous cell carcinoma
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 378KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 56KB)
Nivolumab – July 2023
Nivolumab (gastro-oesophageal cancer): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
27 October 2023